Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

PURPOSE: We compare the efficacy and safety of regorafenib plus immune checkpoint inhibitors (ICIs) with transarterial chemoembolization (R+ICIs+TACE) versus regorafenib plus ICIs (R+ICIs) as the second-line treatment for patients with advanced hepatocellular carcinoma (HCC). METHODS: This retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xuegang, Deng, Heping, Sun, Yanyuan, Zhang, Yi, Lu, Yujie, Xu, Guohui, Huang, Xiaoqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983436/
https://www.ncbi.nlm.nih.gov/pubmed/36874252
http://dx.doi.org/10.2147/JHC.S399135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983436/
https://www.ncbi.nlm.nih.gov/pubmed/36874252
http://dx.doi.org/10.2147/JHC.S399135

Ejemplares similares